Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Neurotoxic phenomena are among the most common and difficult to treat side effects of
chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a
well-recognized adverse reaction in the peripheral nervous system. Side effects of
chemotherapy in the central nervous system, however, particularly changes of cognitive
function (in non-medical literature referred to as "chemobrain") are diffuse and difficult to
attribute to individual cytostatic drugs. The primary purpose of this study is to assess
cognitive function in patients with ovarian and breast cancer before and after systemic
chemotherapy with paclitaxel with standardized neuropsychological tests and compare the
outcome to patients with benign gynecological tumors and breast cancer without chemotherapy
treatment, respectively. Secondary parameters include the assessment of olfactory function,
total neuropathy score and cytokine profiles.